Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-NSCC): Results from the randomized phase II RESGEX study.

被引：4
|
作者：
Keilholz, Ulrich
Kawecki, Andrzej
Dietz, Andreas
Zurawski, Bogdan
Schenker, Michael
Kukielka-Budny, Bozena
Schafhausen, Philippe
Mihailov, Anca C.
Ochenduszko, Sebastian
Imarisio, Ilaria
Mihutiu, Simona
Oprean, Cristina-Marinela
Folprecht, Gunnar
Turcu, Alina
Rottey, Sylvie
Debourdeau, Philippe
Lavernia, Javier
Dietrich, Bruno
Zurlo, Alfredo
Fayette, Jerome
机构：
[1] Charite Comprehens Canc Ctr, Berlin, Germany
[2] M Sklodowska Curie Mem Inst, Canc Ctr, Warsaw, Poland
[3] Univ Leipzig, Leipzig, Germany
[4] F Lukaszczyk Oncol Ctr, Bydgoszcz, Poland
[5] S C Centrul Oncol, Policlin Sf Nectarie, Craiova, Romania
[6] Ctr Oncol, Lublin, Poland
[7] Univ Hamburg Eppendorf, Hamburg, Germany
[8] Univ Hosp Cluj, Cluj Napoca, Romania
[9] Krakow Univ Hosp Oncol Clin, Krakow, Poland
[10] IRCCS San Matteo Univ Hosp Fdn, Dept Med Oncol, Pavia, Italy
[11] Emergency Clin Hosp Oradea, Oradea, Bihor, Romania
[12] ONCOMED SRL, Timisoara, Romania
[13] Univ Hosp Carl Gustav Carus, Dresden, Germany
[14] SPITAL LOTUS SRL, Ploiesti, Romania
[15] Ghent Univ Hosp, Heymans Inst Pharmacol, Ghent, Belgium
[16] Inst Sainte Catherine, Avignon, France
[17] FIVO, Valencia, Spain
[18] Glycotope GmbH, Berlin, Germany
[19] Ctr Leon Berard, Med Oncol, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 05期
关键词：
D O I：
10.1200/JCO.2018.36.5_suppl.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
59
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF AFATINIB VERSUS CETUXIMAB IN RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
    Seiwert, T. Y.
    Fayette, J.
    Cupissol, D.
    DelCampo, J. M.
    Clement, P. M.
    Tourani, J. M.
    Degardin, M.
    Blackman, A. S.
    Cong, J.
    Solca, F.
    Ehrnrooth, E.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2012, 23 : 35 - 35
  • [42] A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Espinosa, E
    Zamora, P
    Millá, A
    Morales, S
    Molina, R
    Mira, M
    Barón, MG
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (12): : 1054 - 1059
  • [43] Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Choong, N. W.
    Cohen, E. E.
    Kozloff, M. F.
    Taber, D.
    Wade, J. L., III
    Hu, S.
    Ivy, S. P.
    Nichols, K.
    Dekker, A.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
    Cohen, EEW
    Rosen, F
    Stadler, WM
    Recant, W
    Stenson, K
    Huo, DZ
    Vokes, EE
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) : 1980 - 1987
  • [45] Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial
    Fayette, J.
    Thomas, G.
    Daste, A.
    Rotarski, M.
    Castelo, B.
    Rullan, A.
    Levine, A.
    Philipson, R. S.
    Harrington, K. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S615 - S616
  • [46] A phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma.
    Karivedu, Vidhya
    Riaz, Muhammad Kashif
    Mathews, Maria
    Kurtzweil, Nicky
    Monroe, Ilaina
    Romano, Audrey
    Wise-Draper, Trisha Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01
    Machiels, Jean-Pascal H.
    Henry, Stephanie
    Zanetta, Sylvie
    Kaminsky, Marie-Christine
    Michoux, Nicolas
    Rommel, Denis
    Schmitz, Sandra
    Bompas, Emmanuelle
    Dillies, Anne-Francoise
    Faivre, Sandrine
    Moxhon, Anne
    Duprez, Thierry
    Guigay, Joel
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 21 - 28
  • [48] Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
    Cohen, Ezra E. W.
    Davis, Darren W.
    Karrison, Theodore G.
    Seiwert, Tanguy Y.
    Wong, Stuart J.
    Nattam, Sreenivasa
    Kozloff, Mark F.
    Clark, Joseph I.
    Yan, Duen-Hwa
    Liu, Wen
    Pierce, Carolyn
    Dancey, Janet E.
    Stenson, Kerstin
    Blair, Elizabeth
    Dekker, Allison
    Vokes, Everett E.
    LANCET ONCOLOGY, 2009, 10 (03): : 247 - 257
  • [49] Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
    Kim, Han Sang
    Kwon, Hyeong Ju
    Jung, Inkyung
    Yun, Mi Ran
    Ahn, Myung-Ju
    Kang, Byung Woog
    Sun, Jong-Mu
    Kim, Sung Bae
    Yoon, Dok-Hyun
    Park, Keon Uk
    Lee, Se-Hoon
    Koh, Yoon Woo
    Kim, Se Hun
    Choi, Eun Chang
    Koo, Dong Hoe
    Sohn, Jin Hee
    Kim, Bomi
    Kwon, Nak-Jung
    Yun, Hwan Jung
    Lee, Min Goo
    Lee, Ji Hyun
    Kim, Tae-Min
    Kim, Hye Ryun
    Kim, Joo Hang
    Paik, Soonmyung
    Cho, Byoung Chul
    CLINICAL CANCER RESEARCH, 2015, 21 (03) : 544 - 552
  • [50] Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma
    Nutting, C. M.
    van Herpen, C. M. L.
    Miah, A. B.
    Bhide, S. A.
    Machiels, J. -P.
    Buter, J.
    Kelly, C.
    de Raucourt, D.
    Harrington, K. J.
    ANNALS OF ONCOLOGY, 2009, 20 (07) : 1275 - 1279
12345